Is the Biotech IPO Window Closing?
This article was originally published in Scrip
Drug developers are filing for initial public offerings at a brisk pace in October despite falling biotechnology stock values and the struggle to price first-time offerings attractively, which begs the question: Are biotech companies afraid that the IPO window is about to close?
You may also be interested in...
Scrip spoke with executives from five companies about challenges that remain for the burgeoning – but still young – immuno-oncology field in Part 2 of a wide-ranging roundtable discussion.
Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.
Wave Life Sciences Ltd. entered into a collaboration agreement with Pfizer Inc. for the discovery and development of nucleic acid therapeutics addressing five metabolic disease targets, adding $40m in upfront cash to its balance sheet that will help the newly public biotechnology firm keep its in-house focus on rare, genetic neurological and neuromuscular diseases.